Acetylator Phenotype in Patients with Hydralazine‐induced Lupoid Syndrome

Publisher Website
Google Scholar
Abstract
The acetylator phenotype was determined (isoniazid half-life) in 31 patients (25 women) who had exhibited a lupus erythematosus-like syndrome during treatment with hydralazine. Twenty-nine patients were slow acetylators, one was rapid (probably spontaneous SLE [systemic lupus erythematosus]) and one uncertain. Only 2 patients were given more than 200 mg of hydralazine daily. The mean duration of therapy was 32 mo. at the onset of symptoms. These were not serious but rather long-standing. Patients who risk developing hydralazine lupus are slow acetylators, especially females, treated with more than 100 mg daily. Rapid acetylators seem to develop this side-effect rarely, if at all.